Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 4 - Incorporating a Model of Human Rights into the Adjudication of Pharmaceutical Patent Cases (Part One)

  • Emmanuel Kolawole Oke
  • Book:
    Patents, Human Rights, and Access to Medicines
    Published online:
    24 February 2022
    Print publication:
    03 March 2022, pp 104-117

  • Summary

    This chapter is structured into three main sections. Section 4.2 provides a brief overview of the legal framework on pharmaceutical patent law in Kenya. Section 4.3 deals with the key issue in this chapter, that is, the incorporation of a model of human rights into the adjudication of disputes involving pharmaceutical patent rights by courts in Kenya. Section 4.4 examines whether, in the light of Article 40(5) of the Kenyan Constitution which provides that the state ‘shall support, promote and protect the intellectual property rights of the people of Kenya’, intellectual property rights can be considered as a human right in Kenya. The chapter concludes with the view that it is essential for courts seeking to protect the right of poor patients to have access to affordable medicines to incorporate a model of human rights when they adjudicate disputes involving pharmaceutical patent rights.